Post-Step modifications for research on HIV vaccines

AIDS

Volumn 23, Issue 1, 2009, Pages 3-8

  Corey, Lawrence ^a   McElrath, M Juliana ^a   Kublin, James G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; VIRUS VECTOR;

ADENOVIRUS 5; BIOMETRY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SEXUAL BEHAVIOR; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; AIDS VACCINES; FEMALE; GENETIC VECTORS; HIV INFECTIONS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTE SUBSETS;

EID: 58149136160     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830e6d6d     Document Type: Review

References (34)

1. Vaccination and enrollment are discontinued in phase II trials of Merck's investigational HIV vaccine candidate. Interim analysis of Step study shows vaccine was not effective. In: Press release from Merck and the HIV Vaccine Trials Network. Whitehouse Station: New Jersey; Seattle, Washington; 21 September 2007.
2. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007; 318:28-29.
3. Mehrotra DV, Li X, Gilbert PB. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof of concept HIV vaccine trial. Biometrics 2006; 62:893-900.
4. Priddy F, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al., Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type-5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769-1781.
5. Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona VVL, Adams-Muhler L, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 2007; 23:67-76.
6. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-372.
7. Isaacs R. Impact of preexisting immunity on the immunogenicity of adenovirus serotype 5-based vaccines [abstract 69]. AIDS Vaccine. Lausanne; 2004.
8. HIV Vaccine Trials Network 2007 Full Group Meeting, http://www.hvtn.org/ science/1107.html Nov 7. [Accessed 24 April 2008.]
9. Buchbinders. Efficacy results from the Step study (Merck V520 Protocol 023/HVTN 502). A phase II test-of-concept trial of the MRKAd5 HIV-1 gag/pol/nef trivalent vaccine. 15th Conference on Retroviruses and Opportunistic Infections: Boston, Massachusetts; 2008.
10. NIAID Bulletin: an update concerning the HVTN 503/Phambili HIV Vaccine Study. http://www3.niaid.nih.gov/news/newsre-leases/2008/hvtn503_update.htm.
11. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature 2002; 415:331-335.
12. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7-12.
13. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547-15555.
14. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt MD, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005; 79:8828-8834.
15. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Cene Ther 2005; 16:149-156.
16. Emini EA. A potential HIV-1 vaccine using a replication-defective adenoviral vaccine vector. Keystone Symposia. Banff, Alberta, Canada; 2003.
17. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Engl J Med 2007; 356:2073-2081.
18. Duerr A, Wasserheit J N, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006; 43:500-511.
19. Li F, McKenney DM, Malhotra U, Crimi C, Nolin J, Corey L, et al. Towards prediction of degenerate CTL epitope recognition. Hum Vaccin 2007; 4:115-121.
20. De Rosa SC, Thomas EP, Huang Y, Morgan C, Kalams S, Graham B, et al. Kinetics of T cell responses to vaccination for HIV and heterologous DNA primar-rAd5 boost contrasted with homologous rAd5 prime-boost [abstract 161]. Keystone Symposia. Banff, Alberta, Canada; 2008.
21. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7:173-178.
22. Nickle DC, Rolland M, Jensen MA, Pond SL, Deng W, Seli gman M, et al. Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 2007; 3:e75.
23. Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG, et al. HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. Curr HIV Res 2007; 5:97-107.
24. Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, et al. Design and preclinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007; 2:e984.
25. Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008; 26:215-223.
26. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 gag-specific TH1 and CD8+ T cell responses. J Immunol 2005; 174:7676-7683.
27. Smith CL, Mirza F, Pasquetto V, Tscharke DC, Palmowski MJ, Dunbar PR, et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 2005; 175:8431-8437.
28. Koopman G, Mortier D, Hofman S, Niphuis H, Fagrouch Z, Norley S, et al. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J Gen Virol 2004; 85 (Pt 10):2915-2924.
29. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-258.
30. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789.
31. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005; 174:1037-1045.
32. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-850.
33. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124:849-863.
34. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203:413-424.